PRCA
MCID: PRR002
MIFTS: 47

Pure Red-Cell Aplasia (PRCA) malady

Categories: Rare diseases, Blood diseases

Aliases & Classifications for Pure Red-Cell Aplasia

Aliases & Descriptions for Pure Red-Cell Aplasia:

Name: Pure Red-Cell Aplasia 12 14 69
Pure Red Cell Aplasia 12 50
Primary Red Cell Aplasia 12
Red-Cell Aplasia, Pure 42
Red-Cell Aplasia Pure 52
Red Cell Hypoplasia 12
Prca 50

Classifications:



External Ids:

Disease Ontology 12 DOID:1340
MeSH 42 D012010
NCIt 47 C34974
UMLS 69 C0034902

Summaries for Pure Red-Cell Aplasia

NIH Rare Diseases : 50 pure red cell aplasia (prca) is a rare condition that affects the bone marrow. bone marrow contains stem cells which develop into the red blood cells that carry oxygen through the body, the white blood cells that fight infections, and the platelets that help with blood clotting. in people with prca, the bone marrow makes a reduced number of red blood cells (called anemia). as a result, affected people may experience fatigue, lethargy, and pale skin. prca has many different causes. a rare congenital form of prca, called diamond blackfan syndrome, is an inherited condition that is also associated with other physical abnormalities. prca can also be due to certain medications, infections, pregnancy, renal failure, and conditions such as thymomas, autoimmune disease (such as systemic lupus erythematosus), cancers of the blood, and solid tumors. in many cases, the cause of the condition is unknown (idiopathic). the treatment of prca aims to address the underlying cause of the condition and relieve the associated signs and symptoms. last updated: 4/21/2016

MalaCards based summary : Pure Red-Cell Aplasia, also known as pure red cell aplasia, is related to hepatitis and acquired pure red cell aplasia. An important gene associated with Pure Red-Cell Aplasia is EPO (Erythropoietin), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Allograft rejection. The drugs Iron and Deferasirox have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells.

Wikipedia : 71 Pure red cell aplasia (PRCA) or erythroblastopenia refers to a type of anemia affecting the precursors... more...

Related Diseases for Pure Red-Cell Aplasia

Diseases related to Pure Red-Cell Aplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 182)
id Related Disease Score Top Affiliating Genes
1 hepatitis 30.7 HLA-A HLA-DRB1 IL2
2 acquired pure red cell aplasia 12.8
3 transient erythroblastopenia of childhood 12.1
4 diamond-blackfan anemia 11.5
5 leukemia 10.7
6 thymoma 10.7
7 hemolytic anemia 10.5
8 lymphoma 10.5
9 lupus erythematosus 10.5
10 systemic lupus erythematosus 10.5
11 autoimmune hemolytic anemia 10.5
12 large granular lymphocyte leukemia 10.5
13 chronic lymphocytic leukemia 10.4
14 hematopoietic stem cell transplantation 10.4
15 myelodysplastic syndrome 10.3
16 myasthenia gravis 10.3
17 hepatitis c 10.3
18 thrombocytopenia 10.3
19 aplastic anemia 10.2
20 hepatitis a 10.2
21 lateral body wall defect 10.2 IL2RA STAT3
22 b-cell lymphomas 10.2
23 kidney disease 10.2
24 arthritis 10.2
25 non-amyloid monoclonal immunoglobulin deposition disease 10.2 HLA-DRB1 IL2RA
26 autoimmune retinopathy 10.2 IL2RA STAT3
27 sacral nerve root cysts 10.2 HLA-A HLA-DRB1
28 ciliary discoordination, due to random ciliary orientation 10.2 ALB IL2RA
29 retroperitoneal germ cell neoplasm 10.2 ALB HLA-DRB1
30 hernia of ovary and fallopian tube 10.2 HLA-A HLA-DRB1
31 learning disability 10.2 HLA-A HLA-DRB1
32 rheumatoid arthritis 10.2
33 caplan's syndrome 10.1 HLA-DRB1 IL2
34 chronic gonococcal salpingitis 10.1 ALB IL2
35 renal agenesis meningomyelocele mullerian defect 10.1 HLA-DRB1 IL2
36 ovarian papillary cystadenoma 10.1 ALB EPO
37 labyrinthine bilateral reactive loss 10.1 ALB IL2
38 aortic coarctation 10.1 HLA-A IL2RA
39 acquired amegakaryocytic thrombocytopenia 10.1
40 viral hepatitis 10.1
41 angioimmunoblastic t-cell lymphoma 10.1
42 diffuse large b-cell lymphoma 10.1
43 celiac disease 10.1
44 chronic graft versus host disease 10.1
45 t-cell large granular lymphocyte leukemia 10.1
46 peritonitis 10.1
47 good syndrome 10.1
48 purpura 10.1
49 adult-onset still's disease 10.1
50 evans' syndrome 10.1

Graphical network of the top 20 diseases related to Pure Red-Cell Aplasia:



Diseases related to Pure Red-Cell Aplasia

Symptoms & Phenotypes for Pure Red-Cell Aplasia

Drugs & Therapeutics for Pure Red-Cell Aplasia

Drugs for Pure Red-Cell Aplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 100)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
2
Deferasirox Approved, Investigational Phase 4,Phase 3,Phase 2 201530-41-8 5493381
3
Darbepoetin alfa Approved, Investigational Phase 4,Phase 2 11096-26-7, 209810-58-2
4 Epoetin alfa Phase 4,Phase 3,Phase 2 113427-24-0
5 Hematinics Phase 4,Phase 3,Phase 2
6 Liver Extracts Phase 4
7 Antibodies Phase 4,Phase 3,Phase 2
8 Immunoglobulins Phase 4,Phase 3,Phase 2
9 Chelating Agents Phase 4,Phase 3,Phase 2
10 Iron Chelating Agents Phase 4,Phase 3,Phase 2
11 Micronutrients Phase 4,Phase 3
12 Trace Elements Phase 4,Phase 3
13
Cyclophosphamide Approved, Investigational Phase 2, Phase 3, Phase 1 50-18-0, 6055-19-2 2907
14
Lenograstim Approved Phase 2, Phase 3 135968-09-1
15
Cyclosporine Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
16
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
17
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
18
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
19
Benzocaine Approved Phase 3,Phase 2 1994-09-7, 94-09-7 2337
20
Busulfan Approved, Investigational Phase 2, Phase 3, Phase 1 55-98-1 2478
21
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
22
Vidarabine Approved Phase 2, Phase 3 24356-66-9 32326 21704
23
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1 216503-57-0
24
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
25
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
26 tannic acid Approved, Nutraceutical Phase 3,Phase 2
27 Alkylating Agents Phase 2, Phase 3, Phase 1
28 Anti-Infective Agents Phase 2, Phase 3, Phase 1
29 Antilymphocyte Serum Phase 2, Phase 3, Phase 1
30 Antineoplastic Agents, Alkylating Phase 2, Phase 3, Phase 1
31 Immunosuppressive Agents Phase 2, Phase 3, Phase 1
32 Antirheumatic Agents Phase 2, Phase 3, Phase 1
33 Antiemetics Phase 3,Phase 2
34 Antifungal Agents Phase 3,Phase 2,Phase 1
35 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
36 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
37 Autonomic Agents Phase 3,Phase 2
38 Calcineurin Inhibitors Phase 3,Phase 2
39 Dermatologic Agents Phase 3,Phase 2
40 Gastrointestinal Agents Phase 3,Phase 2
41 glucocorticoids Phase 3,Phase 2,Phase 1
42 Hormone Antagonists Phase 3,Phase 2,Phase 1
43 Hormones Phase 3,Phase 2,Phase 1
44 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
45 Methylprednisolone acetate Phase 3,Phase 2
46 Methylprednisolone Hemisuccinate Phase 3,Phase 2
47 Neuroprotective Agents Phase 3,Phase 2
48 Peripheral Nervous System Agents Phase 3,Phase 2
49 Prednisolone acetate Phase 3,Phase 2
50 Prednisolone hemisuccinate Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 62)
id Name Status NCT ID Phase
1 A Study of Patients With Pure Red Cell Aplasia Associated With Recombinant Human Erythropoietin Treatment Completed NCT00211042 Phase 4
2 Study to Monitor the Incidence of Pure Red Cell Aplasia (PRCA) and/or Antibodies to Erythropoietin Among Participants Receiving Epoetin Alfa or Another Erythropoietin Completed NCT00210951 Phase 4
3 A Study to Observe the Number of Patients Who Develop Pure Red Cell Aplasia (PRCA, a Rare Form of Anemia) While Receiving Epoetin Alfa or Other Recombinant Erythropoietins Completed NCT00211029 Phase 4
4 A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa Completed NCT00211068 Phase 4
5 Surveillance Study to Estimate the Incidence of Pure Red Blood Cell Aplasia Among Patients With Chronic Kidney Failure Completed NCT00391287 Phase 4
6 Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload Completed NCT00673608 Phase 4
7 A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropo Active, not recruiting NCT00773513 Phase 4
8 Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin Alfa Enrolling by invitation NCT02648126 Phase 4
9 A Study of Patients Treated With Erythropoietin Receptor Agonists for Anemia Who Developed Anti-erythropoietin Antibodies Withdrawn NCT00210977 Phase 4
10 Cohort Study to Determine the Long-Term Safety and Efficacy of Biogeneric Epoetin Treatment for Renal Anemia Unknown status NCT00238043 Phase 3
11 Efficacy and Safety Study of GerEPO Completed NCT00229099 Phase 3
12 Iron Sucrose in Stage 3/4 Kidney Disease Completed NCT00202345 Phase 3
13 Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload Completed NCT00235391 Phase 3
14 Stem Cell Transplant for Bone Marrow Failure Syndromes Completed NCT00176878 Phase 2, Phase 3
15 Stem Cell Transplant for Hemoglobinopathy Active, not recruiting NCT00176852 Phase 2, Phase 3
16 Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) Treatment Terminated NCT01288131 Phase 3
17 A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer Terminated NCT00246597 Phase 3
18 L-leucine in Diamond Blackfan Anemia Patients Unknown status NCT02386267 Phase 2
19 Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia Completed NCT00229619 Phase 2
20 Efficacy and Safety of Peginesatide in the Treatment of Anemia in Patients With Chronic Kidney Disease Completed NCT00314795 Phase 2
21 Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes Completed NCT00004143 Phase 2
22 A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity Completed NCT01044186 Phase 2
23 Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias Completed NCT00061763 Phase 2
24 Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan Anemia Completed NCT00011505 Phase 2
25 Medical Treatment for Diamond Blackfan Anemia Completed NCT00001749 Phase 2
26 Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders Completed NCT00301834 Phase 2
27 Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remi Completed NCT00305708 Phase 1, Phase 2
28 Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure Recruiting NCT02105766 Phase 1, Phase 2
29 Safety and Efficacy Study of Sotatercept in Adults With Transfusion Dependent Diamond Blackfan Anemia Recruiting NCT01464164 Phase 1, Phase 2
30 Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells Recruiting NCT01174108 Phase 2
31 Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow Recruiting NCT00003838 Phase 2
32 Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias Recruiting NCT00061568 Phase 2
33 Pilot Phase I/II Study of Amino Acid Leucine in Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia Active, not recruiting NCT01362595 Phase 1, Phase 2
34 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting NCT01529827 Phase 2
35 Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies Suspended NCT01419704 Phase 1, Phase 2
36 A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure Terminated NCT00001962 Phase 2
37 The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias Terminated NCT00472433 Phase 2
38 A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002) Terminated NCT00968617 Phase 2
39 A Study of the Efficacy and Safety of MK2578 for the Treatment of Anemia in Patients With Kidney Disease (MK2578-003-AM03-EXT12) Terminated NCT00924781 Phase 2
40 Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs Terminated NCT00957931 Phase 2
41 Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells Terminated NCT02512679 Phase 2
42 Human Placental-Derived Stem Cell Transplantation Recruiting NCT01586455 Phase 1
43 BMT Abatacept for Non-Malignant Diseases Recruiting NCT01917708 Phase 1
44 Identifying Characteristics of Bone Marrow Failure Syndromes Unknown status NCT00315419
45 Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Unknown status NCT00006055
46 Multi-Center Study of Iron Overload: Survey Study (MCSIO) Unknown status NCT01913548
47 Multi-Center Study of Iron Overload: Pilot Study Unknown status NCT01114776
48 Cytokine Gene Polymorphisms in Bone Marrow Failure Completed NCT00085670
49 Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders Completed NCT00005893
50 Stem Cell Transplantation (SCT) for Genetic Diseases Completed NCT00004378

Search NIH Clinical Center for Pure Red-Cell Aplasia

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: red-cell aplasia, pure

Genetic Tests for Pure Red-Cell Aplasia

Anatomical Context for Pure Red-Cell Aplasia

MalaCards organs/tissues related to Pure Red-Cell Aplasia:

39
Bone, Bone Marrow, T Cells, Skin, B Cells, Kidney, Liver

Publications for Pure Red-Cell Aplasia

Articles related to Pure Red-Cell Aplasia:

(show top 50) (show all 623)
id Title Authors Year
1
Pure red cell aplasia due to antibody against erythropoietin in hemodialysis patients. ( 28042550 )
2017
2
Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib. ( 27756158 )
2017
3
Simultaneous occurrence of autoimmune hemolytic anemia and pure red cell aplasia. ( 28090019 )
2016
4
Successful high-dose dexamethasone treatment of acquired pure red cell aplasia following ABO major mismatched allogeneic hematopoietic stem cell transplantation. ( 27384857 )
2016
5
Thymoma with Concomitant Pure Red Cell Aplasia, Good's Syndrome and Myasthenia Gravis Responding to Rituximab. ( 27408396 )
2016
6
A cluster of Epoetin-associated pure red cell aplasia: clinical features and the possible association of HLA-DRB1*12:02. ( 27348021 )
2016
7
Pure red cell aplasia revealing nonnodal mantle cell lymphoma. ( 27322005 )
2016
8
Pure red cell aplasia caused by parvovirus B19 in a heart transplant recipient. ( 27648265 )
2016
9
Pure Red Cell Aplasia Following Interleukin-2 Therapy. ( 27144182 )
2016
10
TKI-induced pure red cell aplasia: first case report of pure red cell aplasia with both imatinib and nilotinib. ( 27843612 )
2016
11
Pure Red Cell Aplasia and Autoimmune Hemolytic Anemia Sequentially Occurring in a Patient with Large Granular T-lymphocytic Leukemia. ( 27250059 )
2016
12
Monoclonal gammopathy-associated pure red cell aplasia. ( 26999424 )
2016
13
Chronic persistent parvovirus B19 bone marrow infection resulting in transfusion-dependent pure red cell aplasia in multiple myeloma after allogeneic haematopoietic stem cell transplantation and severe graft versus host disease. ( 27311084 )
2016
14
Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. ( 26921820 )
2016
15
Invasive Thymoma with Pure Red Cell Aplasia and Amegakaryocytic Thrombocytopenia. ( 28053696 )
2016
16
Dapsone-induced pure red cell aplasia and cholestatic jaundice: A new experience for diagnosis and management. ( 27512715 )
2016
17
Pure red cell aplasia due to azathioprine therapy for Crohn's disease. ( 26997730 )
2016
18
Post renal transplant pure red cell aplasia-is tacrolimus a culprit? ( 27478605 )
2016
19
Pure red cell aplasia. ( 27881371 )
2016
20
Linezolid Induced Twice Pure Red Cell Aplasia in a Patient with Central Nervous System Infection after Allogeneic Stem Cell Transplantation. ( 27642338 )
2016
21
Epoetin-I^ induced pure red cell aplasia: an unintended consequence. ( 27932518 )
2016
22
Immunotherapy-Associated Hemolytic Anemia with Pure Red-Cell Aplasia. ( 26981948 )
2016
23
Coombs-negative Autoimmune Hemolytic Anemia Followed by Anti-erythropoetin Receptor Antibody-associated Pure Red Cell Aplasia: A Case Report and Review of Literature. ( 26935373 )
2016
24
Pure red cell aplasia induced by anti-erythropoietin antibodies, well-controlled with tacrolimus. ( 27338269 )
2016
25
Pure red cell aplasia. ( 27913462 )
2016
26
Unusual co-occurrence of Evans syndrome and pure red cell aplasia in elderly patient with prostate cancer. ( 27465154 )
2016
27
Cyclosporine restores hematopoietic function by compensating for decreased Tregs in patients with pure red cell aplasia and acquired aplastic anemia. ( 26968551 )
2016
28
Pure red cell aplasia induced by epoetin zeta. ( 27478604 )
2016
29
Moderate-dose cyclophosphamide in the treatment of relapsed/refractory T-cell large granular lymphocytic leukemia-associated pure red cell aplasia. ( 27077768 )
2016
30
Holoprosencephaly and Pure Red Cell Aplasia in a Feline Leukaemia Virus-Positive Kitten. ( 26897097 )
2016
31
Cardiovascular Morbidity and Pure Red Cell Aplasia Associated With Epoetin Theta Therapy in Patients With Chronic Kidney Disease: A Prospective, Noninterventional, Multicenter Cohort Study. ( 26708119 )
2016
32
Primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab. ( 27382560 )
2016
33
Recurrent pure red cell aplasia in a hepatorenal transplant recipient with chronic parvovirus B19 infection. ( 26457576 )
2015
34
Rituximab: A viable treatment option for epoetin-induced pure red cell aplasia. ( 26664213 )
2015
35
A novel interstitial deletion of 2q22.3 q23.3 in a patient with dysmorphic features, epilepsy, aganglionosis, pure red cell aplasia, and skeletal malformations. ( 25988649 )
2015
36
Persistent I^I' T large granular lymphocytosis in a patient with refractory pure red cell aplasia, celiac disease, and chronic hepatitis B infection. ( 26515990 )
2015
37
Pure red cell aplasia due to anti-erythropoietin antibodies or isoniazid? A case report from a 94-year-old man. ( 25597021 )
2015
38
Successful treatment of refractory pure red cell aplasia with bortezomib after allogeneic haematopoietic cell transplantation in a patient with alpha-beta subcutaneous panniculitis-like T cell lymphoma. ( 26147536 )
2015
39
Long-term outcome of patients with acquired chronic pure red cell aplasia (PRCA) following immunosuppressive therapy: a final report of the nationwide cohort study in 2004/2006 by the Japan PRCA collaborative study group. ( 25807974 )
2015
40
Anti-Erythropoietin Antibody Associated Pure Red Cell Aplasia Resolved after Liver Transplantation. ( 26240773 )
2015
41
Cyclosporine dependent pure red cell aplasia: a case presentation. ( 25488615 )
2015
42
Oral High Dose Dexamethasone for Pure Red Cell Aplasia Following ABO-Mismatched Allogeneic Peripheral Blood Stem Cell Transplantation: A Case Report. ( 25825583 )
2015
43
Treatment of pure red cell aplasia associated with multiple myeloma with biclonal gammopathy using cyclosporine A: a case report. ( 25785163 )
2015
44
Human parvovirus B19 infection induced pure red cell aplasia in liver transplant recipients. ( 26177162 )
2015
45
Azathioprine-associated pure red cell aplasia in renal transplant recipients: a report of two cases. ( 23680868 )
2014
46
Rituximab in pure red-cell aplasia secondary to anti-erythropoietin antibodies. ( 24978384 )
2014
47
Persistent pure red cell aplasia in dicygotic twins with persistent congenital parvovirus B19 infection-remission following high dose intravenous immunoglobulin. ( 25269997 )
2014
48
Systemic lupus erythematosus complicated with thymoma and pure red cell aplasia (PCRA). CR of both complications following thymectomy and allogeneic haematopoietic SCT (HSCT), but persistence of antinuclear antibodies (ANA). ( 24820215 )
2014
49
Pure red cell aplasia induced by lamivudine without the influence of zidovudine in a patient infected with human immunodeficiency virus. ( 25088890 )
2014
50
Clozapine Administration and the Risk of Drug-Related Pure Red Cell Aplasia: A Novel Case Report. ( 25289460 )
2014

Variations for Pure Red-Cell Aplasia

Expression for Pure Red-Cell Aplasia

Search GEO for disease gene expression data for Pure Red-Cell Aplasia.

Pathways for Pure Red-Cell Aplasia

Pathways related to Pure Red-Cell Aplasia according to GeneCards Suite gene sharing:

(show all 23)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.11 HLA-A HLA-DRB1 IL2 IL2RA STAT3
2
Show member pathways
12.6 HLA-A HLA-DRB1 IL2 IL2RA
3
Show member pathways
12.49 HLA-A HLA-DRB1 IL2 IL2RA STAT3
4
Show member pathways
12.38 HLA-DRB1 IL2 IL2RA TRB
5
Show member pathways
12.19 HLA-DRB1 IL2 IL2RA STAT3 TRB
6 12.17 HLA-A HLA-DRB1 IL2 IL2RA
7
Show member pathways
12.16 HLA-DRB1 IL2 IL2RA
8 12.06 HLA-A HLA-DRB1 STAT3
9
Show member pathways
11.91 EPO IL2 IL2RA STAT3
10
Show member pathways
11.85 IL2 IL2RA STAT3
11
Show member pathways
11.81 IL2 IL2RA STAT3
12 11.75 EPO IL2 IL2RA
13 11.67 EPO STAT3 TF
14 11.64 EPO HLA-DRB1 IL2RA
15
Show member pathways
11.39 HLA-A IL2 IL2RA
16 11.28 EPO IL2 IL2RA STAT3
17
Show member pathways
11.21 IL2 IL2RA
18
Show member pathways
11.15 HLA-A HLA-DRB1 IL2 IL2RA STAT3 TRB
19 11.11 IL2 IL2RA
20 11.08 IL2 TRB
21
Show member pathways
11.03 IL2RA STAT3
22 10.97 HLA-DRB1 IL2 TRB
23 10.7 HLA-DRB1 IL2 IL2RA STAT3

GO Terms for Pure Red-Cell Aplasia

Cellular components related to Pure Red-Cell Aplasia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.02 EPO HLA-A HLA-DRB1 IL2RA TF
2 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 8.96 HLA-A HLA-DRB1

Biological processes related to Pure Red-Cell Aplasia according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.76 ALB EPO IL2 STAT3
2 immune response GO:0006955 9.73 HLA-A HLA-DRB1 IL2 IL2RA
3 immune system process GO:0002376 9.67 HLA-A HLA-DRB1 IL2 IL2RA
4 retina homeostasis GO:0001895 9.51 ALB TF
5 negative regulation of T cell proliferation GO:0042130 9.49 HLA-DRB1 IL2RA
6 acute-phase response GO:0006953 9.48 EPO STAT3
7 positive regulation of T cell differentiation GO:0045582 9.4 IL2 IL2RA
8 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.32 EPO IL2
9 inflammatory response to antigenic stimulus GO:0002437 9.26 HLA-DRB1 IL2RA
10 negative regulation of lymphocyte proliferation GO:0050672 9.16 IL2 IL2RA
11 regulation of T cell homeostatic proliferation GO:0046013 8.96 IL2 IL2RA
12 positive regulation of activated T cell proliferation GO:0042104 8.8 EPO IL2 IL2RA

Molecular functions related to Pure Red-Cell Aplasia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 8.62 HLA-A HLA-DRB1

Sources for Pure Red-Cell Aplasia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....